Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Completed 9Recruiting 7Unknown 4Active not recruiting 4Terminated 3Not yet recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 69Carcinoma, Non-Small-Cell Lung 60Stomach Neoplasms 32Prostatic Neoplasms 21Nasopharyngeal Carcinoma 20Lung Neoplasms 20Squamous Cell Carcinoma of Head and Neck 11Esophageal Neoplasms 10Neoplasm Metastasis 8Head and Neck Neoplasms 7Inflammatory Breast Neoplasms 6Pancreatic Neoplasms 5Neoplasms 5HER2-positive Breast Cancer 5Triple Negative Breast Neoplasms 4Ovarian Neoplasms 4NSCLC 4Carcinoma, Squamous Cell 4Adenocarcinoma 4Sarcoma 3Nasopharyngeal Neoplasms 3Hypopharyngeal Neoplasms 3Esophageal Squamous Cell Carcinoma 3Carcinoma, Ovarian Epithelial 3Breast Diseases 3Adenocarcinoma of Lung 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Tongue Neoplasms 2Squamous Cell Lung Cancer 2

Interventions

Carboplatin 15camrelizumab 11Capecitabine 11130-nm albumin-bound paclitaxel 10pembrolizumab 8eribulin 8Paclitaxel 8Cyclophosphamide 7Gemcitabine 6Epirubicin 6Cisplatin 6apatinib 5tislelizumab 4atezolizumab 4anlotinib 4Taxes 4Nivolumab 4Docetaxel 4Bevacizumab 4Vinorelbine 3N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Doxorubicin 3toripalimab 2talazoparib 2spartalizumab 2olaparib 2fluzoparib 2famitinib 2Zoledronic Acid 2Metformin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Unknown × Triple Negative Breast Neoplasms × Docetaxel × Clear all
NCT03639948 2024-04-11

NeoPACT

University of Kansas Medical Center

Phase 2 Unknown
120 enrolled 12 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05088057 2021-10-21

Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer

Jilin University

Phase 2 Unknown
30 enrolled
Breast

Triple Negative Breast Neoplasms

NCT01642771 2017-04-19

Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer

China Breast Cancer Clinical Study Group

Phase 3 Unknown
636 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02685657 2016-02-22

Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer

Russian Academy of Medical Sciences

Phase 2 Unknown
164 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡